Conclusions
The serendipitous finding that grapefruit juice interacts with felodipine was subsequently found to be valid for some other dihydropyridines, but this interaction is probably not limited to this class of drugs. The clinical relevance of the grapefruit juice interaction with each particular drug will depend on the magnitude of change in the pharmacokinetic profile of the drug, the drug concentration-response relationships and the patient. Since current information indicates that the interaction is variable and unpredictable, it appears reasonable to caution patients not to ingest grapefruit juice at the same time as taking felodipine and other dihydropyridines. Identification of the active ingredient in grapefruit juice may allow the prediction of other foods that may also interact with dihydropyridines and some other drugs. Furthermore, it may lead to exploitation of the inhibitory effects of the active ingredient(s), and its inclusion into drug formulations to increase the clinical efficacy of orally administered drugs. It seems that this discovery has provided fundamental new knowledge both to improve pharmacotherapy and to stimulate further research.
Similar content being viewed by others
References
Abernethy DR, Schwartz JB. Pharmacokinetics of calcium antagonists under development. Clinical Pharmacokinetics 15: 1–14, 1988
Bailey DG, Arnold JMO, Munoz C, Spence JD. Grapefruit juice-felodipine interaction: mechanism, predictability and effect of naringin. Clinical Pharmacology and Therapeutics 53: 637–642, 1993a
Bailey DG, Arnold JMO, Strong HA, Munoz C, Spence JD. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clinical Pharmacology and Therapeutics 54: 589–594, 1993b
Bailey DG, Arnold JMO, Tran LT, Ahktar J, Spence JD. Marked effects of both erythromycin and grapefruit juice on felodipine pharmacokinetics. Abstract. Clinical Pharmacology and Therapeutics 55: in press, 1994
Bailey DG, Munoz C, Arnold JMO, Strong HA, Spence JD. Grapefruit juice and naringin interaction with nitrendipine. Abstract. Clinical Pharmacology and Therapeutics 51: 156, 1992
Bailey DG, Spence JD, Edgar B, Bayliff CD, Arnold JMO. Ethanol enhances the hemodynamic effects of felodipine. Clinical and Investigative Medicine 12: 357–362, 1989
Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 337: 268–269, 1991
Blychert E, Edgar B, Elmfeldt D, Hedner T. A population study of the pharmacokinetics of felodipine. British Journal of Clinical Pharmacology 31: 15–24, 1991
Blychert E, Hedner T, Dahlof C, Elmfeldt D. Plasma-concentration effect relationships of intravenous and extended release oral felodipine in hypertensive patients. Journal of Cardiovascular Pharmacology 15: 428–435, 1990
Brun J, Froberg L, Kronmann P, Olsson LB, Skoog P, et al. Optimal felodipine dose when combined with metoprolol in arterial hypertension: a Swedish multicentre study with primary health care. Journal of Cardiovascular Pharmacology 15 (Suppl. 4): S60–S64, 1990
Buening MK, Chang RL, Huang MT, Fortner JG, Wood AW, et al. Activation and inhibition of benzo(a)pyrene and aflatoxin B-1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Research 41: 67–72, 1981
Chayen R, Rosenthal T. Interaction of citrus juices with felodipine and nifedipine. Letter. Lancet 337: 854, 1991
Dow RJ, Graham DJM. A review of the human metabolism and pharmacokinetics of nicardipine hydrochloride. British Journal of Clinical Pharmacology 22: 195S–202S, 1986
Ducharme MP, Provenzano R, Dehoorne-Smith M, Edwards DJ. Trough concentrations of cyclosporine following administration with grapefruit juice. British Journal of Clinical Pharmacology 36: 457–459, 1993
Dunselman PHJM, Edgar B. Felodipine clinical pharmacokinetics. Clinical Pharmacokinetics 21: 418–430, 1991
Edgar B, Bailey DG, Bergstrand R, Johnsson G, Lurje L. Formulation dependent interaction between felodipine and grapefruit juice. Abstract. Clinical Pharmacology and Therapeutics 47: 181, 1990
Edgar B, Bailey DG, Bergstrand R, Johnsson G, Regårdh CG. Acute effect of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine — and its potential clinical relevance. European Journal of Clinical Pharmacology 42: 313–317, 1992
Edgar B, Lundborg P, Regårdh CG. Clinical pharmacokinetics of felodipine a summary. Drugs 34 (Suppl. 3): 16–27, 1987
Friedel HA, Sorkin EM. Nisoldipine: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 36: 682–731, 1988
Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. British Journal of Clinical Pharmacology 35: 431–436, 1993
Gaffield W, Lundin RE, Gentili B, Horowitz RM. C-2 stereocheochemistry of naringin and its relation to taste and biosynthesis in maturing grapefruit. Bioorganic Chemistry 4: 259–269, 1975
Goa KL, Sorkin EM. Nitrendipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 33: 123–155, 1987
Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C, et al. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P450IIIA4. Journal of Medicinal Chemistry 34: 1838–1844, 1991
Guengerich FP, Kim DH. In vitro inhibition of dihydropyridine oxidation and aflatoxin B-1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11: 2275–2279, 1990
Krause M, Galensa R. High-performance liquid chromatography of diastereomeric flavanone glycosides of citrus on a β-cyclodextrinbonded stationary phase (Cycloband I). Journal of Chromatography 588: 41–45, 1991
Kuhnau J. The flavonoids: a class of semi-essential food components. Their role in human nutrition. World Review of Nutrition and Dietetics 24: 117–191, 1976
Leenen FHH, Logan AG, Myers MG, Elkan I, Canadian Felodipine Study Group. Antihypertensive efficacy of the calcium antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. British Journal of Clinical Pharmacology 26: 535–545, 1988
Levitt AD, Zweiffler AJ. Nifedipine, hypotension and myocardial injury. Letter. Annals of Internal Medicine 108: 305–306, 1988
Miniscalco A, Lundahl J, Regårdh CG, Edgar B, Eriksson UG. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. Journal of Pharmacology and Experimental Therapeutics 261: 1196–1199, 1992
O’Mailia JJ, Sander GE, Giles TD. Nifedipine-associated myocardial ischemia or infarction in the treatment of hypertensive urgencies. Annals of Internal Medicine 107: 185–186, 1987
Rashid J, McKinstry C, Renwick AG, Dirnhuber M, Waller DG, et al. Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. British Journal of Clinical Pharmacology 36: 460–463, 1993
Regårdh CG, Baarnhielm C, Edgar B, Hoffmann KJ. Pharmacokinetics and biotransformation of 1,4-dihydropyridine calcium antagonists. Progress in Drug Metabolism 12: 41–86, 1990
Regårdh CG, Edgar B, Olsson R, Kendall M, Collste P, et al. Pharmacokinetics of felodipine in patients with liver disease. European Journal of Clinical Pharmacology 36: 473–479, 1989
Soons PA, Vogels BAPM, Roosemalen MCM, Schoemaker HC, Uchida E, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in man. Clinical Pharmacology and Therapeutics 50: 394–403, 1991
Sorkin EM, Clissold SP, Brogden RN. Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties and efficacy in ischemic heart disease, hypertension and related cardiovascular disorders. Drugs 30: 182–274, 1985
Svensson CK, Edwards DJ, Mauriello PM, Barde SH, Foster AC, et al. Effect of food on hepatic blood flow: implications in the ‘food effect’ phenomenon. Clinical Pharmacology and Therapeutics 34: 316–323, 1983
Wang SX, Sutfin TA, Baarnhielm C, Regårdh CG. Contribution of the intestine to the first-pass metabolism of felodipine in the rat. Journal of Pharmacology and Experimental Therapeutics 250: 632–636, 1989
Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Editorial. Circulation 84: 2599–2600, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bailey, D.G., Arnold, J.M.O. & Spence, J.D. Grapefruit Juice and Drugs. Clin. Pharmacokinet. 26, 91–98 (1994). https://doi.org/10.2165/00003088-199426020-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199426020-00002